ANALISIS BIAYA PENGOBATAN GAGAL JANTUNG PADA PASIEN RAWAT INAP DI RSUD KABUPATEN KARANGANYAR TAHUN 2011-2012

SYAFRIAH, WA ODE (2013) ANALISIS BIAYA PENGOBATAN GAGAL JANTUNG PADA PASIEN RAWAT INAP DI RSUD KABUPATEN KARANGANYAR TAHUN 2011-2012. Tesis thesis, Universitas setia budi.

[img] Text
BAB I.pdf

Download (491kB)
[img] Text
BAB II.pdf
Restricted to Repository staff only

Download (161kB) | Request a copy
[img] Text
BAB III.pdf
Restricted to Repository staff only

Download (51kB) | Request a copy
[img] Text
bab IV.pdf
Restricted to Repository staff only

Download (142kB) | Request a copy
[img] Text
BAB V.pdf

Download (16kB)
[img] Text
BAB VI.pdf

Download (410kB)
[img] Text
INTI SARI.pdf

Download (28kB)

Abstract

Heart failure is the second highest disease after acute myocardial infarction. Heart failure is a disease that requires care that requires a very high cost. The purposes this research are to determine treatment patterns of heart failure, the average cost of treatment, the factors that affect the total cost and the compliance of real packet costs of INA-CBGs patient. This study is an observational study using a study design perspective hospital. In this study the data retrieved retrospectively and quantitative data. The sample used was a heart failure patient who is hospitalized in Karanganyar district hospitals in 2011-2012. The data obtained were analyzed using descriptive test to determine patient characteristics, comorbid, length of treatment, description of treatment patterns, and costs on average. Correlation test was conducted to determine the factors that influence the cost of treating heart failure patients and the one sample t-test to determine the real cost of compliance with health costs based on cost INA-CBG's. Based on the results of the study concluded that the description of the pattern of treatment were digoksin 21 (20.79%), ISDN 16 (15.84%) and captopril 15 (14,85%). The real cost average of heart failure stage B of general patient 1.460.012, jamkesmas patients 929.325,55, and jamkesda patient 1.305.095,33, and stage C for general patient 1.193.882,71, jamkesmas patient 1.065.896,64 and jamkesda patient 1.137.514,69. Factors affecting the cost of treating heart failure hospitalization was longer (p <0.005), and comorbid (p <0.005). The research results showed that the average real treatment cost of heart failure non comorbid and comorbid was different significantly with INA-CBGs package cost. Keywords: Cost Analysis, Heart Failure, INA-CBGs

Item Type: Thesis (Tesis)
Uncontrolled Keywords: Cost Analysis, Heart Failure, INA-CBGs
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Fakultas Farmasi > Prodi S2 Farmasi
Depositing User: Mrs NOVI HANDAYANI
Date Deposited: 01 Nov 2019 07:43
Last Modified: 01 Nov 2019 07:43
URI: http://repository.setiabudi.ac.id/id/eprint/3223

Actions (login required)

View Item View Item